Trial · NCT04191096
Adverse events648
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 648
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab + Enzalutamide + ADT | 97 | 625 | 139 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + Enzalutamide + ADT | 85 | 625 | 108 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab + Enzalutamide + ADT | 82 | 625 | 82 |
| other | Hypothyroidism | Endocrine disorders | Placebo + Enzalutamide + ADT | 25 | 625 | 25 |
| other | Abdominal pain | Gastrointestinal disorders | Pembrolizumab + Enzalutamide + ADT | 32 | 625 | 41 |
| other | Abdominal pain | Gastrointestinal disorders | Placebo + Enzalutamide + ADT | 29 | 625 | 33 |
| other | Constipation | Gastrointestinal disorders | Pembrolizumab + Enzalutamide + ADT | 108 | 625 | 133 |
| other | Constipation | Gastrointestinal disorders | Placebo + Enzalutamide + ADT | 103 | 625 | 117 |
| other | Diarrhoea | Gastrointestinal disorders | Pembrolizumab + Enzalutamide + ADT | 127 | 625 | 196 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo + Enzalutamide + ADT | 73 | 625 | 92 |
| other | Nausea | Gastrointestinal disorders | Pembrolizumab + Enzalutamide + ADT | 105 | 625 | 125 |
| other | Nausea | Gastrointestinal disorders | Placebo + Enzalutamide + ADT | 75 | 625 | 86 |
| other | Vomiting | Gastrointestinal disorders | Pembrolizumab + Enzalutamide + ADT | 35 | 625 | 43 |
| other | Vomiting | Gastrointestinal disorders | Placebo + Enzalutamide + ADT | 29 | 625 | 36 |
| other | Asthenia | General disorders | Pembrolizumab + Enzalutamide + ADT | 80 | 625 | 101 |
| other | Asthenia | General disorders | Placebo + Enzalutamide + ADT | 55 | 625 | 66 |
| other | Fatigue | General disorders | Pembrolizumab + Enzalutamide + ADT | 194 | 625 | 236 |
| other | Fatigue | General disorders | Placebo + Enzalutamide + ADT | 178 | 625 | 200 |
| other | Oedema peripheral | General disorders | Pembrolizumab + Enzalutamide + ADT | 67 | 625 | 73 |
| other | Oedema peripheral | General disorders | Placebo + Enzalutamide + ADT | 50 | 625 | 54 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04191096/events